A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thrombopro-phylaxis after total hip and total knee replacement in the irish healthcare setting - McCullagh, L; Tilson, L; Walsh, C (Pharmacoeconomics, 2009)